Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
September 12, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale
September 12, 2022 07:30 ET
|
Theratechnologies
Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
September 12, 2022 07:30 ET
|
Theratechnologies
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 10, 2022 04:00 ET
|
Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
September 10, 2022 03:05 ET
|
POINT Biopharma
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
September 09, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
September 09, 2022 01:15 ET
|
Novartis Pharma AG
New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with...
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy
September 08, 2022 16:05 ET
|
Alpha Tau Medical Ltd.
– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American...
Florida Cancer Specialists & Research Institute Physicians Present Cancer Care Advancements at Global Oncology Gathering
September 08, 2022 12:30 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the latest cutting-edge developments and findings...
GRYT Health to Host Fourth Annual Global Virtual Cancer Conference (GVCC) in November 2022
September 08, 2022 09:00 ET
|
GRYT Health
ROCHESTER, N.Y., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GRYT ("grit") Health, a patient experience and research company, is hosting the fourth annual Global Virtual Cancer Conference (GVCC) from Nov....